tbuckley/cabot-search huggingface dataset:
Abstract 271: Continuous Amplitude Spectral Area May Reflect Adequacy of Myocardial Perfusion Before Attempting Defibrillation
Authors: Raúl J Gazmuri, Christopher L Kaufman, Herbert K Whitehouse, Alvin Baetiong, Jeejabai Radhakrishnan
Journal: Circulation (2014)

Background: Previous studies have shown that analysis of the VF amplitude-spectral area (AMSA) contains information predictive of electrical shock success. However, the underlying factors that determine AMSA remain elusive. We developed an open-chest swine model of VF in which we modeled “average CPR” followed by “highly effective CPR” using extracorporeal circulation (ECC) and assessed AMSA in relation to adequacy of coronary perfusion. Methods: VF was electrically induced and left untreated for 8 min in 8 pigs after which ECC was started and maintained for 10 min adjusting the flow to generate a coronary perfusion pressure (CPP) of 10 mmHg (low-flow ECC). After delivery of an initial shock, the ECC flow was increased and titrated to secure a mean aortic pressure of 40 mmHg (high-flow ECC) delivering additional electrical shocks at 60 s intervals. Blood flow through the left anterior descending (LAD) artery was reported relative to baseline (LAD rel). AMSA was measured continuously with a 2.1 s timeframe and a Tukey window that moved ahead every 0.5 s, and was averaged every min for this report (Figure). Results: AMSA increased during the initial 5 min of low-flow ECC, but subsequently decreased (Figure). The initial shock uniformly failed to terminate VF prompting increases in ECC to high-flow, which then resulted in the return of spontaneous circulation in each instance after 3 to 5 shocks. During the high-flow ECC, AMSA initially increased but then gradually decreased for reasons that are not clear. Before attempting defibrillation, AMSA was positively correlated with LAD rel (r=0.73, p=0.04). Conclusion: The study provides intriguing data showing changes in AMSA that are time dependent and likely influenced by myocardial perfusion and the effects of electrical shocks on the myocardium. The present study also suggests that the level of AMSA prior to attempting defibrillation may be influenced by the efficacy with which the CPR intervention generates coronary blood flow.
Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells
Authors: Gerty Schreibelt, Kalijn F. Bol, Harm Westdorp, Florian Wimmers, Erik H.J.G. Aarntzen, Tjitske Duiveman-de Boer, Mandy W.M.M. van de Rakt, Nicole M. Scharenborg, Annemiek J. de Boer, Jeanette M. Pots, Michel A.M. Olde Nordkamp, Tom G.M. van Oorschot, Jurjen Tel, Gregor Winkels, Katja Petry, Willeke A.M. Blokx, Michelle M. van Rossum, Marieke E.B. Welzen, Roel D.M. Mus, Sandra A.J. Croockewit, Rutger H.T. Koornstra, Joannes F.M. Jacobs, Sander Kelderman, Christian U. Blank, Winald R. Gerritsen, Cornelis J.A. Punt, Carl G. Figdor, I. Jolanda M. de Vries
Journal: Clinical Cancer Research (2015)

Thus far, dendritic cell (DC)-based immunotherapy of cancer was primarily based on in vitro-generated monocyte-derived DCs, which require extensive in vitro manipulation. Here, we report on a clinical study exploiting primary CD1c(+) myeloid DCs, naturally circulating in the blood.Fourteen stage IV melanoma patients, without previous systemic treatment for metastatic disease, received autologous CD1c(+) myeloid DCs, activated by only brief (16 hours) ex vivo culture and loaded with tumor-associated antigens of tyrosinase and gp100.Our results show that therapeutic vaccination against melanoma with small amounts (3-10 × 10(6)) of myeloid DCs is feasible and without substantial toxicity. Four of 14 patients showed long-term progression-free survival (12-35 months), which directly correlated with the development of multifunctional CD8(+) T-cell responses in three of these patients. In particular, high CD107a expression, indicative for cytolytic activity, and IFNγ as well as TNFα and CCL4 production was observed. Apparently, these T-cell responses are essential to induce tumor regression and promote long-term survival by stalling tumor growth.We show that vaccination of metastatic melanoma patients with primary myeloid DCs is feasible and safe and results in induction of effective antitumor immune responses that coincide with improved progression-free survival. Clin Cancer Res; 22(9); 2155-66. ©2015 AACR.
Castleman disease variant of atypical POEMS syndrome: A case presentatIon
Authors: Zeynep Isikdogan, Ayse Baha, Nurdan Kokturk, Haluk Turktas, Nalan Akyurek, Gulsan Sucak
Journal: European Respiratory Journal (2014)

POEMS syndrome is a rare multisystemic disorder characterized by polyneuropathy, organomegaly, monoclonal gammopathy and skin lesions.Here we present a case of Castleman disease variant of atypical POEMS syndrome presented with organomegaly,mediastinal conglomerate lymph nodes,bilateral pulmonary involvement,monoclonal gammopathy,elevated IL-6 levels, anemia and thrombosis but no polyneuropathy.A 40 year-old female was presented with a history of dyspnea, fever and 20 kilograms of weight loss in four months.Thorax computerized tomography revealed bilateral conglomerate hilar and mediastinal lymph nodes,bilateral diffuse parenchymal consolidations and multiple parenchymal spiculated nodules.Fiberoptic bronchoscopy showed no morphological pathology,bronchoscopic biopsy specimens had no specific diagnosis.Diagnostic mediastinoscopy session was terminated because of the increased fibrotic tissue.Hence, patient was undergone thoracotomy and multinodular,dense lymphoplasmocytic infiltration was seen in biopsy specimens.Immunohistochemistry studies showed no specific pathology.The bone scintigraphy and the knee magnetic resonance imaging revealed cortical erosion at distal femur, which showed kappa monoclonal plasma cell infiltration at biopsy.IL-6 level was elevated and electromyography showed no polyneuropathy.On the basis of the findings of conglomerate lymphadenopathy,monoclonal gammopathy, organomegaly,anemia, elevated IL-6 levels and trombocytosis, patient was diagnosed with Castleman disease variant of atypical POEMS syndrome.Atypical and multisystemic rare diseases should be kept in mind in the differential diagnosis of a patients with interstitial lung disease with unusual presentation.
Plaque Prolapse After Stenting in Myocardial Infarction: Bad Plaque—Bad Omen?
Authors: Tim A. Fischell
Journal: JACC. Cardiovascular imaging (2008)

In this issue of iJACC (JACC: Cardiovascular Imaging) , Hong et al. ([1][1]) have made a number of interesting observations regarding the relatively high incidence (27%) and poorer prognosis associated with the intravascular ultrasound finding of tissue prolapse through stent struts in the setting
Cytogenetic abnormalities in myelofibrosis determined by FISH
Authors: N. Zojer, K. Strasser-Weippl, M. Steurer, M. Kees, F. Augustin, A. Tzankov, S. Dirnhofer, J. Thiele, H. Gisslinger, H. Ludwig
Journal: Journal of Clinical Oncology (2004)

9611 Background: An abnormal karyotype has been correlated with poor prognosis in myelofibrosis with myeloid metaplasia (MMM) in several recent studies. This may be due to an increased proliferative index in these cases. However, conventional cytogenetics is usually hampered by the difficulty of obtaining sufficient numbers of analyzable metaphases from bone marrow aspirates in MMM. This obstacle can be overcome by fluorescence in situ hybridization (FISH), which can be performed on interphase nuclei from archival material. Methods: In this study, the bone marrow of 107 patients with MMM was analyzed using FISH and chromosomal probes 7cen, 7q, 8cen, 20q, 11cen, 12p, 13q, 17cen, 17p, 21q. Cases with myelodysplastic features or a known bcr/abl translocation were excluded from analysis. The prognostic impact of individual cytogenetic lesions on survival was evaluated using multivariate analysis. Results: In univariate analysis, -7/7q- was significantly associated with inferior outcome (median survival 99 vs. 25 months, p<0.001). This abnormality remained significant in a multivariate analysis including all cytogenetic parameters, our own myelofibrosis prognostic index (MPI) and the LILLE prognostic score. When a cytogenetic risk indicator (CPI), based on several cytogenetic variables, was used, patients were clearly divided into two groups with a significantly distinct outcome. Conclusions: Detection of loss of 7/7q by FISH was found to be significantly associated with inferior outcome in MMM. Multivariate analysis including established prognostic factors identified deletion of 7/7q as independent prognostic factor in patients with MMM. By using cytogenetic findings only, patients can be allocated into poor and good risk groups. No significant financial relationships to disclose.
Dnmt3a regulates myeloproliferation and liver-specific expansion of hematopoietic stem and progenitor cells
Authors: O A Guryanova, Y K Lieu, F E Garrett-Bakelman, B Spitzer, J L Glass, K Shank, A B V Martinez, S A Rivera, B H Durham, F Rapaport, M D Keller, S Pandey, L Bastian, D Tovbin, A R Weinstein, J Teruya-Feldstein, O Abdel-Wahab, V Santini, C E Mason, A M Melnick, S Mukherjee, R L Levine
Journal: Leukemia (2015)
An Open-Label, Randomized Phase II Trial of Personalized Peptide Vaccination in Patients with Bladder Cancer that Progressed after Platinum-Based Chemotherapy
Authors: Masanori Noguchi, Kazumasa Matsumoto, Hirotsugu Uemura, Gaku Arai, Masatoshi Eto, Seiji Naito, Chikara Ohyama, Yasutomo Nasu, Masatoshi Tanaka, Fukuko Moriya, Shigetaka Suekane, Satoko Matsueda, Nobukazu Komatsu, Tetsuro Sasada, Akira Yamada, Tatsuyuki Kakuma, Kyogo Itoh
Journal: Clinical Cancer Research (2015)

The prognosis of platinum-based chemotherapy-resistant metastatic urothelial cancer of the bladder remains poor. Personalized selection of the right peptides for each patient could be a novel approach for a cancer vaccine to boost anticancer immunity.In this randomized, open-label, phase II study, patients ages ≥18 years with progressive bladder cancer after first-line platinum-based chemotherapy were randomly assigned (1:1) to receive personalized peptide vaccination (PPV) plus best supportive care (BSC) or BSC. PPV treatment used a maximum of four peptides chosen from 31 candidate peptides according to human leukocyte antigen types and peptide-reactive IgG titers, for 12 s.c. injections (8 injections, weekly; 4 injections, bi-weekly). The primary endpoint was progression-free survival (PFS). Secondary endpoints were overall survival (OS), immune response, and toxicity.Eighty patients were randomly assigned to receive either PPV plus BSC (n = 39) or BSC (n = 41). No significant improvement in PFS was noted [HR, 0.7; 95% confidence interval (CI), 0.4-1.2, P = 0.17]. For the secondary endpoints, PPV plus BSC significantly prolonged OS compared with BSC (HR, 0.58; 95% CI, 0.34-0.99, P = 0.049), with median OS of 7.9 months (95% CI, 3.5-12.0) in the PPV plus BSC and 4.1 months (95% CI, 2.8-6.9) in the BSC. PPV treatment was well tolerated, without serious adverse drug reactions.PPV could not prolong PFS, but OS appeared to be improved with low toxicity and immune responses. Further large-scale, randomized trials are needed to confirm these results.
The Importance of Assessing Neural Trajectories in Pediatric Depression
Authors: Ian H. Gotlib, Sarah J. Ordaz
Journal: JAMA Psychiatry (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
The Role of Radiotherapy in the Management of Intra-Cerebral Metastases
Authors: D. Ash
Journal: Neuro-Oncology (1980)

The overall incidence of cerebral metastases found at post mortem in patients dying of cancer is 15–20%. 60–70% of cases have multiple metastases in the brain and the majority are found in the cerebral hemispheres though approximately 20% may be in the cerebellum. Lung cancer and breast cancer are by far the commonest tumours which metastasise to the brain. In lung cancer the brain may be the only site of the metastasis in approximately 75% of cases whereas in breast cancer approximately 75% of cases of brain metastasis are associated with metastases elsewhere.
Phase II Trial of Temozolomide and Irinotecan as Second-Line Treatment for Advanced Non–small Cell Lung Cancer
Authors: Nicholas W. Choong, Ann M. Mauer, Philip C. Hoffman, Charles M. Rudin, Jerome D. Winegarden, J Lee Villano, Mark Kozloff, James L. Wade, David F. Sciortino, Livia Szeto, Everett E. Vokes
Journal: Journal of Thoracic Oncology (2006)
ATM deficiency promotes development of murine B-cell lymphomas that resemble diffuse large B-cell lymphoma in humans
Authors: Karen S. Hathcock, Hesed M. Padilla-Nash, Jordi Camps, Dong-Mi Shin, Daniel Triner, Arthur L. Shaffer, Robert W. Maul, Seth M. Steinberg, Patricia J. Gearhart, Louis M. Staudt, Herbert C. Morse, Thomas Ried, Richard J. Hodes
Journal: Blood (2015)
FRI0405 Sub-analysis of elf score biomarkers components indicates a specific correlation with different organ involvement in systemic sclerosis
Authors: G. Abignano, G. Cuomo, M. Buch, W. M. Rosenberg, G. Valentini, P. Emery, F. Del Galdo
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> A recent large multicenter study has identified an algorithm, known as Enhanced Liver Fibrosis (ELF), by combining the serum concentrations of amino-terminal propeptide of procollagen type III (PIIINP), tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) and hyaluronic acid (HA). The algorithm has been shown to predict liver related outcomes in patients with chronic liver diseases and recently it has been shown to correlate with several measures of fibrosis in Systemic Sclerosis (SSc). <h3>Objectives</h3> The aim of this study was to compare the ability of ELF and its single components in correlating with the different clinical and instrumental variables to determine whether any of the three biomarkers could have a specific role as surrogate outcome measure in SSc. <h3>Methods</h3> The serum concentrations of the three biomarkers were analysed in 210 SSc patients employing the same platform used to calculate the ELF score (Siemens, Advia Centaur). All patients were investigated for clinical features, skin and internal organs involvement, HAQ-DI, disease severity and activity. Statistical analysis was performed using GraphPrism software. <h3>Results</h3> Correlation coefficients are shown in the table. All three components of ELF showed a significant correlation with mRSS and were higher in patients with flexion contractures (p&lt;0.05). Interestingly, the concentration of HA was the only parameter correlating with age, muscle and heart involvement. The biomarker with better correlation with lung involvement was TIMP-1, which showed a significant correlation with DLCO% predicted value and lung severity and the serum levels were significantly higher in patients with lung fibrosis as assessed by HRCT scan (p&lt;0.0001). All three serum markers correlated with HAQ-DI and both PIIINP and TIMP-1 with the EScSG-AI. <h3>Conclusions</h3> Sub-analysis of the single serum markers included in the ELF score algorithm suggests that the different biomarkers may function as surrogate outcome measure of specific organ involvement in SSc. In this regard, longitudinal studies assessing the sensitivity to change over time of the single biomarkers may pave the way to develop specific algorithms tailored to carry the maximum predictive value on specific organ involvement in SSc. <h3>Disclosure of Interest</h3> None Declared
Other American studies fail to confirm an association
Authors: S. H. Zahm, A. Blair, K. P Cantor, J. F Fraumeni Jr
Journal: BMJ (1995)

ED1TOR,-We agree with Helen Ward and John S Yudkin that diabetic retinopathy should not be a contraindication to the use of thrombolysis in myocardial infarction.'In September 1991 one of us (RCW) expressed concern locally that the practical difficulty of excluding diabetic retino- pathy could easily lead to diabetic patients being denied thrombolysis.The need for a rapid decision, often without the benefit of case notes and after opiate analgesia, posed particular problems for the receiving team.Subsequently, discussion took place in Mersey region among diabetologists, ophthalmologists, and cardiologists in their respective subcommittees of the regional medical committee.It was agreed that diabetic retinopathy should no longer be regarded as a contraindication to thrombolysis for two reasons: firstly, the potential benefits of a
Statistical Aspects of Extrapolation of Dichotomous Dose-Response Data
Authors: Charles C. Brown
Journal: JNCI Journal of the National Cancer Institute (1978)

Journal Article Statistical Aspects of Extrapolation of Dichotomous Dose-Response Data Get access Charles C. Brown Charles C. Brown 2Biometry Branch, National Cancer Institute, National Institutes of Health, Public Health Service, U.S. Department of Health, Education, and Welfare, Bethesda, Md. 20014. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 60, Issue 1, January 1978, Pages 101–108, https://doi.org/10.1093/jnci/60.1.101 Published: 01 January 1978 Article history Received: 25 July 1975 Revision received: 31 May 1977 Accepted: 05 July 1977 Published: 01 January 1978
Binding of &lt;italic&gt;Ulex europaeus&lt;/italic&gt; Agglutinin-I in Polyposis Coli: Comparative Study With Solitary Adenoma in the Sigmoid Colon and Rectum&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: S Yonezawa, T Nakamura, S Tanaka, K Maruta, M Nishi, E Sato
Journal: JNCI Journal of the National Cancer Institute (1983)

Our previous lectin-binding study of the human colorectal mucosa revealed that, in the distal large bowel, Ulex europaeus agglutinin-L (UEA-l) binding was detectable in adenocarcinomas and adenomas, whereas it usually was not found in the normal epithelium. The aim of the present study was to obtain further information about the chemical nature of the constituents of the epithelium in polyposis coli and solitary colorectal adenoma. UEA-l binding to demonstrate alpha-L-fucosyl residue-containing glycoproteins was conducted on entire colon specimens from 4 patients with polyposis coli and on polypectomy specimens from 23 patients with solitary adenomas of the sigmoid colon and rectum with the use of a highly sensitive lectin-antilectin immunoperoxidase method. In the rectosigmoid area of all 4 patients with polyposis coli, positive UEA-l staining was observed not only in the adenomatous epithelium but also in the nonneoplastic epithelium intervening between the polyps. In contrast, in 18 of 23 patients with solitary adenomas, positive UEA-l staining was observed only in the adenomatous epithelium but not in the adjacent nonneoplastic epithelium. In the remaining 5 solitary adenomas, UEA-l staining was shown neither in the adenomatous epithelium nor in the adjacent nonneoplastic epithelium.
new treatment modalities
Authors: M Cobbold, J Polefrone, J Qian, F Mohammed, A Norris, A De Santis, A Zarling, J Shabanowitz, B Willcox, M Williams, D Hunt, V Engelhard, J Brody, W Ai, D Czerwinski, R Advani, S Horning, R Hoppe, R Levy, J Timmerman, D Betting, R Yamada, K Steward, K Kafi, S Schuster, B Levine, C Andreadis, S Nasta, N Aqui, B Musher, J Cotte, Z Zheng, A Cannon, L Downs, A Mato, E Chong, E Veloso, C June, I Micallef, M Maurer, D Nikcevich, M Cannon, D Moore, P Kurtin, E Schaefer, T Witzig, M Fanale, H Burris, L Yee, J Lucas, K Dimick, M Goldwasser, W Novotny, G Bray
Journal: Annals of Oncology (2008)
Molecular subtypes of breast cancer and cyclooxygenase-2 overexpression: Predictive role in patients treated with adjuvant anthracycline-based chemotherapy
Authors: Marcella Mottolese, Elisa Melucci, Simonetta Buglioni, Alessandra Fabi, Cecilia Nistico, Francesco Cognetti, Raffaele Perrone-Donnorso, Letizia Perracchio, Irene Venturo, Paola Papaldo, Isabella Sperduti, Pier Giorgio Natali
Journal: Cancer Research (2008)

AACR Annual Meeting-- Apr 12-16, 2008; San Diego, CA

3621 

High levels of cyclooxygenase-2 (COX-2), an inducible enzyme involved in prostaglandin biosynthesis, have been shown to correlate with a worse prognosis in patients with several types of tumors including breast cancer (BC). Moreover, epidemiological, experimental and clinical studies have collectively identified COX-2 as a relevant target for the prevention and treatment of a variety of epithelial malignancies overexpressing this enzyme. Purpose of our study is to evaluate the prognostic value of COX-2 in the context of chemoresponsiveness in BC patients submitted to anthracycline-based adjuvant therapy. We further analyzed the potential differences in treatment effect due to COX-2 expression within the BC molecular subtypes, namely luminal A, basal-like, HER2, normal-like, as defined by immunohistochemistry. To this end, 186 stage I-IIA-B BC patients enrolled in a prospective clinical trial using epirubicin plus cyclophosphamide in the adjuvant setting were investigated using immunohistochemical methods.    COX-2 overexpression was significantly associated to nodal status (p=0.01) and proliferation index (Ki67) (p=0.009). We evidenced a lower percentage of COX-2 positive tumors in the basal-like subtype than in the other three groups. This difference was statistically significant (p=0.022). Multivariate analysis (COX model) indicated that COX-2 was an independent prognostic variable influencing disease free survival (DFS) (HR=3.82, CI=1.54-9.50, p=0.004), but not overall survival (OS). We also estimated the DFS and OS within the four BC subtypes according to COX-2 overexpression demonstrating that a significant higher probability of relapsing, but not of dying was observed in COX-2 positive luminal A (p=0.03) and basal-like (p=0.05) BC. In contrast, the outcomes of HER2 (p=0.11) and normal-like (p=0.66) subtypes were not affected by COX-2 overexpression. The current data suggest that, in our series, COX-2 up-regulation may be strongly informative in predicting response to adiuvant anthracycline therapy mainly in two subtypes, luminal A and basal-like, usually characterized by significant differences in prognosis and response to therapy. In this context, treatment with selective inhibitors of COX-2 may be an additional therapeutic option. Supported by AIRC, Lega Italiana per la Lotta contro i Tumori, Ministero della Salute.
Response to comment on “Dengue virus NS1 protein activates cells via Toll-like receptor 4 and disrupts endothelial cell monolayer integrity” and “Dengue virus NS1 triggers endothelial permeability and vascular leak that is prevented by NS1 vaccination”
Authors: Katryn J. Stacey, Daniel Watterson, Naphak Modhiran, Paul R. Young
Journal: Science Translational Medicine (2015)

Multiple risk factors may cause progression to severe dengue.